FDA Drugs · Jun 12, 2026
Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development – Joint FDA/EMA Workshop - 09/25/2026
Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development – Joint FDA/EMA Workshop
Latest medical news · page 188
The latest headlines across every section, pulled from official and open-access sources.
MHRA (UK) · Jun 12, 2026
Lower dose needle-free allergy treatment approved for younger children
As with any medicine, the MHRA will keep the safety and effectiveness of the adrenaline nasal spray under close review.
PLOS Medicine · Jun 12, 2026
Placenta accreta spectrum in the 21st century: Challenging dogma and redefining disorder
by Eric Jauniaux, Helena C. Bartels, Yalda Afshar Placenta accreta spectrum (PAS) is a serious pregnancy complication caused by abnormal placental attachment to the uterus. In this Perspective, Eric Jauniaux and colleagues discuss emerging evidence that challenges our long-held pathophysiological understanding of PAS, and argue that a critical reassessment of definition, diagnosis, and management is overdue. In this Perspective, Jonathan Evans and colleagues discuss why restricting access to joint replacement surgery based on BMI alone is not supported by evidence, and highlight how such rest…
PLOS Medicine · Jun 12, 2026
Comparison of count-based and clustering definitions of multimorbidity and their association with prevalence of multimorbidity, health profiles, and mortality: A cohort study of UK Biobank participants
by Gabriella C. Silva, Aurore Fayosse, Louis Jacob, Séverine Sabia, Archana Singh-Manoux, Benjamin Landré Background Multimorbidity, the presence of several chronic conditions, is linked to higher mortality and healthcare use and thus poses a major challenge for aging populations. While most studies rely on simple counts of conditions, clustering approaches have been proposed to describe patterns of co-occurring diseases. We aimed to evaluate the extent to which these methodological choices influence prevalence and association with health profiles and mortality. Methods and findings Using UK…
ACP · Jun 12, 2026
Student loans, vaccine access and medicare stability at forefront of topics discussed at ACP Leadership Day 2026
ACP members met with members of Congress to discuss the importance of physician engagement and protecting patients' access to care.
FDA Drugs · Jun 12, 2026
FDA Drug Competition Action Plan
FDA's Drug Competition Action Plan (DCAP) encourages robust and timely market competition for generic drugs and helps bring greater efficiency and transparency to the generic drug review process, without sacrificing the scientific rigor underlying our generic drug program.
MedCity News · Jun 12, 2026
Stop Presenting at Health-Tech Buyers — Let Them Drive
Winning in health-tech is about giving buyers enough operational clarity, early enough, that they can say yes with confidence rather than saying yes because the alternative is another six months of the same evaluation cycle. The post Stop Presenting at Health-Tech Buyers — Let Them Drive appeared first on MedCity News .
MedCity News · Jun 12, 2026
Reliable Transportation Isn’t a Luxury — It’s an Important Part of Cancer Care
Insecurity about transportation can lead to missed appointments and delayed care, and obstacles are more common for cancer patients than for the general population. The post Reliable Transportation Isn’t a Luxury — It’s an Important Part of Cancer Care appeared first on MedCity News .
NCQA · Jun 12, 2026
Turning Data Into Action: A Playbook for Advancing Health Equity
Healthcare organizations across the country are committed to improving health equity—but many struggle with a fundamental question: how do you measure progress in a meaningful, actionable way? A new resource, Cracking the Code: A Health Equity Analytics Implementation Playbook for Healthcare Organizations, helps answer that question. The playbook offers a structured, practical approach for using […] The post Turning Data Into Action: A Playbook for Advancing Health Equity appeared first on NCQA .
FDA Drugs · Jun 12, 2026
Newly Added Guidance Documents
Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.
WHO · Jun 12, 2026
Safe blood supply improves as voluntary donations exceed 85%, but many people still lack access
New data from the World Health Organization (WHO) show sustained progress towards safer blood supplies globally but also highlight persistent inequalities in access to safe blood and weaknesses in governance, financing and regulation of blood systems.
DHSC (UK) · Jun 12, 2026
Official Statistics: Adult social care client level data, England: quarterly update to March 2027
Official statistics in development on insights from client level data from local authorities, including information on assessments and long-term support.
EMA (EU) · Jun 12, 2026
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 June 2026
PRAC concludes evidence of potential risk of neurodevelopmental disorders in children born to men treated with valproate is inconsistent Committee recommends updating product…, Agenda Agenda of the PRAC meeting 8-11 June 2026Draft Reference Number: EMA/PRAC/115322/2026…, PRAC statistics: June 2026 , , Glossary Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between…
Drugs@FDA · Jun 12, 2026
FDA expands Keytruda Qlex (pembrolizumab, berahyaluronidase alfa-pmph) approval
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Merck Sharp Dohme
Drugs@FDA · Jun 12, 2026
FDA expands Truqap (capivasertib) approval
Efficacy supplement (new or revised indication). tablet, oral. Sponsor: Astrazeneca
Drugs@FDA · Jun 12, 2026
FDA expands Keytruda (pembrolizumab) approval
Efficacy supplement (new or revised indication). solution, intravenous. Sponsor: Merck Sharp Dohme
Drugs@FDA · Jun 12, 2026
FDA expands Tzield (teplizumab-mzwv) approval
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Provention Bio Inc
Drugs@FDA · Jun 12, 2026
FDA expands Welireg (belzutifan) approval
Efficacy supplement (new or revised indication). tablet, oral. Sponsor: Merck Sharp Dohme
Drugs@FDA · Jun 12, 2026
FDA expands Skyrizi (risankizumab-rzaa) approval
Efficacy supplement (new or revised indication). injectable, injection. Sponsor: Abbvie Inc
DHSC (UK) · Jun 12, 2026
Official Statistics: Adult social care client level data, England: quarterly update to June 2026
Official statistics in development on insights from client level data from local authorities, including information on assessments and long-term support.
MedlinePlus (NLM) · Jun 12, 2026
Vagus nerve stimulation
Source: Medical Encyclopedia Related MedlinePlus Pages: Depression , Epilepsy , Seizures
MedlinePlus (NLM) · Jun 12, 2026
GLP-1 agonists
Source: Medical Encyclopedia Related MedlinePlus Pages: Diabetes Medicines , Weight Control
DHSC (UK) · Jun 12, 2026
Statutory guidance: Alternative Provider Medical Services (APMS) Directions
Directions for the NHS from the Secretary of State for Health and Social Care relating to Alternative Provider Medical Services (APMS) contracts in general practice.
DHSC (UK) · Jun 12, 2026
Statutory guidance: Alternative Provider Medical Services (APMS) Directions: previous directions
These previous directions, published for public reference, were for the NHS from the Secretary of State for Health and Social Care and relate to APMS contracts in general practice.